These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3990723)

  • 21. [Reconversion of long-standing atrial flutter and fibrillation to sinus rhythm, with oral verapamil and digoxin. Description of 3 cases].
    Mazzoli V; Malmusi A; Scalori G
    G Clin Med; 1985; 66(1-2):57-61. PubMed ID: 4007343
    [No Abstract]   [Full Text] [Related]  

  • 22. Behavioral and electrophysiological studies of chronic oral administration of L-type calcium channel blocker verapamil on learning and memory in rats.
    Lashgari R; Motamedi F; Zahedi Asl S; Shahidi S; Komaki A
    Behav Brain Res; 2006 Aug; 171(2):324-8. PubMed ID: 16707172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic comparison of oral and intravenous verapamil in atrial fibrillation.
    Follath F; Fromer M; Meier P; Vozeh S
    Clin Invest Med; 1980; 3(1-2):49-52. PubMed ID: 7009004
    [No Abstract]   [Full Text] [Related]  

  • 24. Oral verapamil effectively suppressed complex ventricular arrhythmias and unmasked U waves in a patient with Andersen-Tawil syndrome.
    Erdogan O; Aksoy A; Turgut N; Durusoy E; Samsa M; Altun A
    J Electrocardiol; 2008; 41(4):325-8. PubMed ID: 18353348
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction of infarct size by early use of oral propranolol and verapamil in acute myocardial infarction.
    Gupta RC; Sharma SK; Arora YK; Tripathi K
    J Assoc Physicians India; 1985 Sep; 33(9):577-80. PubMed ID: 4093403
    [No Abstract]   [Full Text] [Related]  

  • 26. [Discrepant effects of oral and intravenous verapamil on A-V conduction in patients with ventricular preexcitation and atrial fibrillation].
    Petri H; Kafka W; Rudolph W
    Herz; 1983 Jun; 8(3):144-52. PubMed ID: 6347850
    [No Abstract]   [Full Text] [Related]  

  • 27. [Evaluation of the antihypertensive effect of verapamil, a long-term study].
    Carrasco RM; Luna RL
    Arq Bras Cardiol; 1981 Mar; 36 Suppl 1():41-3. PubMed ID: 7325862
    [No Abstract]   [Full Text] [Related]  

  • 28. [Antihypertensive effect of verapamil. Studies on and experiences with children].
    Dieckmann L; Hösemann R
    MMW Munch Med Wochenschr; 1974 Mar; 116(10):515-20. PubMed ID: 4206420
    [No Abstract]   [Full Text] [Related]  

  • 29. St John's wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism.
    Tannergren C; Engman H; Knutson L; Hedeland M; Bondesson U; Lennernäs H
    Clin Pharmacol Ther; 2004 Apr; 75(4):298-309. PubMed ID: 15060508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of early phase adjuvant arthritis on hepatic P450 enzymes and pharmacokinetics of verapamil: an alternative approach to the use of an animal model of inflammation for pharmacokinetic studies.
    Ling S; Jamali F
    Drug Metab Dispos; 2005 Apr; 33(4):579-86. PubMed ID: 15659540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma levels and urinary excretion of verapamil, norverapamil, N-dealkylverapamil (D617), N-dealkylnorverapamil (D620) following oral administration of a slow-release preparation.
    Barbieri E; Padrini R; Piovan D; Toffoli M; Cargnelli G; Trevi G; Ferrari M
    Int J Clin Pharmacol Res; 1985; 5(2):99-107. PubMed ID: 4018947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Verapamil in the treatment of schizophrenia.
    Wells BG
    DICP; 1990 Sep; 24(9):838-40. PubMed ID: 2260342
    [No Abstract]   [Full Text] [Related]  

  • 33. Once-daily verapamil.
    Dunn JM; Groth PE
    Lancet; 1984 Dec; 2(8415):1338-9. PubMed ID: 6150346
    [No Abstract]   [Full Text] [Related]  

  • 34. Treatment of schizophrenia with verapamil.
    Price WA; Pascarzi G; Giannini AJ
    J Clin Psychopharmacol; 1986 Aug; 6(4):249. PubMed ID: 3734147
    [No Abstract]   [Full Text] [Related]  

  • 35. A systematic review of calcium channel antagonists in bipolar disorder and some considerations for their future development.
    Cipriani A; Saunders K; Attenburrow MJ; Stefaniak J; Panchal P; Stockton S; Lane TA; Tunbridge EM; Geddes JR; Harrison PJ
    Mol Psychiatry; 2016 Oct; 21(10):1324-32. PubMed ID: 27240535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopaminergic function in rat brain after oral administration of calcium-channel blockers or haloperidol. A microdialysis study.
    Reiriz J; Ambrosio S; Cobos A; Ballarín M; Tolosa E; Mahy N
    J Neural Transm Gen Sect; 1994; 95(3):195-207. PubMed ID: 7865175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Time-course of changes in water, sodium, potassium and calcium contents of various brain regions in rats after systemic kainic acid administration.
    Sztriha L; Joó F; Szerdahelyi P
    Acta Neuropathol; 1986; 70(2):169-76. PubMed ID: 3739624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticonvulsant effects of some calcium entry blockers in DBA/2 mice.
    De Sarro GB; Meldrum BS; Nisticó G
    Br J Pharmacol; 1988 Feb; 93(2):247-56. PubMed ID: 3359104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Verapamil. An updated review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension.
    McTavish D; Sorkin EM
    Drugs; 1989 Jul; 38(1):19-76. PubMed ID: 2670511
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Do calcium antagonists have a place in the treatment of mood disorders?
    Höschl C
    Drugs; 1991 Nov; 42(5):721-9. PubMed ID: 1723370
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.